---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-001506"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:29:57.734857+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edgewise Q3 net loss $17.5M ($0.34/shr); cash $365M; EDG-5506 shows biomarker reductions

## Summary
- Cash, equivalents and marketable securities $365M as of Sept 30, 2022; underwritten offering raised $129M net.
- Net loss $17.5M ($0.34 per share) vs $16.1M ($0.32) prior quarter; R&D spend $13.9M.
- Positive 6-month ARCH interim data: CK reduced 39%, fast skeletal troponin I reduced 75% in BMD adults.
- CANYON Phase 2 trial in BMD (n≈66) and LYNX Phase 2 trial in DMD (n≈27) both advancing; no approved treatments.
- EDG-002 preclinical program targets hypertrophic cardiomyopathy; IND-enabling studies planned for 2022.

## SEC filing metadata
- accession: 0001157523-22-001506
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000115752322001506/0001157523-22-001506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000115752322001506/a52959492.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-001506
- JSON: https://secwatch.observer/filing/0001157523-22-001506.json
- Plain text: https://secwatch.observer/filing/0001157523-22-001506.txt

## Key facts
- Earnings Releases
  Edgewise Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000115752322001506/0001157523-22-001506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.